Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma

European Journal of Cancer

Volumn 36, Issue 7, 2000, Pages 881-888

  Coley, H M ^a,c   Verrill, M W ^a,b   Gregson, S E ^a   Odell, D E ^a   Fisher, C ^b   Judson, I R ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Doxorubicin sensitivity; MDR reversal; P glycoprotein; Sarcoma

Indexed keywords

DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; IFOSFAMIDE; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMOSENSITIVITY; CHILD; CLINICAL ARTICLE; DRUG ACCUMULATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHILD; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; P-GLYCOPROTEIN; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034092081     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00032-0     Document Type: Article

References (21)

1. Serra M., Scotlandi K., Manara M.C.et al. Cytotechnology. 19:1996;253-256.
2. Nakanishi H., Myoui A., Ochi T., Aozasa K. P-glycoprotein expression in soft tissue sarcomas. J. Cancer Res. Clin. Oncol. 123:1997;352-356.
3. Hijazi Y.M., Constantine A.A., Navarro S., Steinberg S.M., Horowitz M.E., Tsokos M. Immunohistochemical detection of p-glycoprotein in Ewing's sarcoma and peripheralprimitive neuroectodermal tumors before and after chemotherapy. Anatomic. Path. 102:1994;61-67.
4. Vergier B., Cany L., Bonnet F., Robert J., de Mascarel A., Coindre J.M. Expression of MDR1/Pglycoprotein in human sarcomas. Br. J. Cancer. 68:1993;1221-1226.
5. Gerlach J.H., Bell D.R., Karakousis C.et al. P-glycoprotein in human sarcoma. evidence formultidrug resistance J. Clin. Oncol. 5:1987;1452-1460.
6. Chan H.S.L., Thorner P.S., Haddad G., Ling V. Immunohistochemical detection of p-glycoprotein. prognostic correlation in soft tissue sarcoma of childhood J. Clin. Oncol. 8:1990;689-704.
7. Goldstein L.J., Galski H., Fojo A.et al. Expression of a multidrug resistance gene in humancancers. J. Natl. Cancer Inst. 81:1989;116-124.
8. Toffoli G., Frustaci S., Tumiotto L.et al. Expression of MDR1 and GST pi in human soft tissue sarcomas. relation to drug resistance and biological aggressiveness Ann. Oncol. 3:1992;63-69.
9. Oda Y., Schneider-Stock R., Rys J., Gruchala A., Niezabitowski A., Roessner A. Expression of multidrug resistance associated protein gene in human soft tissue sarcomas. J. Cancer Res. Clin. Oncol. 122:1996;161-165.
10. Coley H.M., Verrill M.V., Gregson S.E., Judson I.R. Drug resistance mechanisms in adult soft tissue sarcomas (STS) using primary and established cultures. Proc. AACR. 37:1996;2119.
11. Coley H.M., Verrill M.W., Judson I.R., Fisher C. P53 abnormalities influence modulation ofMDR in primary cultures of adult soft tissue sarcoma. Proc. AACR. 38:1997;2612.
12. Coley H.M. Drug resistance studies using fresh human ovarian carcinoma and soft tissue sarcoma samples. Keio. J. Med. 46:1997;142-147.
13. Beck W.T., Grogan T.M., Willman C.L.et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors. consensus recommendations Cancer Res. 56:1996;3010-3020.
14. Nojima T., Yi-Song W., Abe S., Matsuno T., Yamawaki S., Nagashima K. Morphological and cytogenetic studies of a human synovial sarcoma xenotransplanted into nude mice. Acta Pathologica Japonica. 40:1990;486-493.
15. Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R. Biological properties often human ovarian carcinoma cell lines. calibration in vitro against four platinum complexes Br. J. Cancer. 59:1989;527-534.
16. Yanagisawa T., Newman A., Coley H.M., Renshaw J., Pinkerton C.R., Pritchard-Jones K. BIROCODAR (VX-710; Incel™) - an effective chemosensitiser in neuroblastoma. Br. J. Cancer. 80:1999;1190-1196.
17. Sosabowski J., Carnochan P., Coley H.M., Judson I.R. Development and evaluation of novel PET radiotracer probes for multidrug resistance (MDR) using a transplantable rat sarcoma. Proc. AACR. 38:1997;3979.
18. Coley H.M., Lewandowicz G., Sargent J.M., Verrill M.W. Chemosensitivity testing of fresh and continuous tumour cell cultures using lactate dehydrogenase. Anticancer Res. 17:1997;231-236.
19. Verrill M.W., Coley H.M., Judson I.R., Fisher C. Susceptibility of fibromatosis cells in short term culture to ifosfamide: a possible new approach to the treatment of clinically aggressive cases. Sarcoma. 3:1999;79-84.
20. Levine A., Holzmayer T., Bacus S.et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J. Clin. Oncol. 15:1997;3249-3257.
21. Broxterman H.J., Sonneveld P., Feller N.et al. Quality control of multidrug resistance assays in adult acute leukaemia. correlation between assays for p-glycoprotein expression and activity Blood. 87:1996;4809-4816.